Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Byondis
Biotech
Yet another exec departs CRISPR Tx—Chutes & Ladders
Yet another exec departs CRISPR Tx. Aurion CEO replaced after power struggle. Another NIH leader hits the exit.
Darren Incorvaia
,
Zoey Becker
Mar 28, 2025 8:30am
Byondis breast cancer drug fails to bloom as FDA denies approval
May 16, 2023 8:28pm
Byondis ready to link up to bring Herceptin-booster to market
Jun 8, 2021 12:25pm
